Articles of Interest Archive

May 2013

• Maxson J et al.
  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
  N Engl J Med 2013 May 9; 368:1781-1790
• Drilon A et al.
  Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
  Cancer Discov 2013 Epub May 7
• Gautschi O et al.
  A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib.
  J Thorac Oncol 2013 May;8(5):e43-4

April 2013

• Mazieres J et al.
  Lung Cancer That Harbors a HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives.
  J. Clin. Oncol. 2013 Epub Apr 22
• Van Allen EM et al.
  Clinical analysis and interpretation of cancer genome data
  J Clin Oncol. 2013 Epub Apr 15
• Trunzer K et al.
  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
  J. Clin. Oncol. 2013 Epub Apr 8
• Wu YM et al.
  Identification of targetable FGFR gene fusions in diverse cancers.
  Cancer Discov 2013 Epub Apr 4
• Lindeman NI et al.
  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Assoc. for Molecular Pathology
  J Thorac Oncol 2013. Epub Apr 2.
• Yeh P et al.
  DNA-mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A catalogue of clinically relevant cancer mutations to enable genome-directed cancer therapy.
  Clin. Cancer Res. 2013 Apr 1; 19(7):1–8.

March 2013

• Rudin CM et al.
  Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer
  J Thorac Oncol. 2013. Epub Mar 21.
• Klein O et al.
  BRAF inhibitor activity in V600R metastatic melanoma.
  Eur. J. Cancer 2013 Mar;49(5):1073-9

February 2013

• Catalanotti F et al.
  Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K-mutated melanoma.
  Clin. Cancer Res. 2013 Epub Feb 26.
• Ho AL et al.
  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer
  N. Engl. J. Med. 2013 Feb 14;368:623-32
• Falchook GS et al.
  BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
  Oncotarget 2013 Feb; 4(2):310-5
• Arcila ME et al.
  EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics.
  Mol. Cancer Ther. 2013 Feb;12(2):220-9
• Kim KB et al.
  Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor.
  J. Clin. Oncol. 2013 Feb 1;31(4):482-9

January 2013

• Advani RH et al.
  Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies.
  J. Clin. Oncol. 2013 Jan 1;31(1):88-94

December 2012

• Wu Y et al.
  Identifying the status of genetic lesions in cancer clinical trial documents using machine learning.
  BMC Genomics 2012 ;13 Suppl 8:S21
• Callahan MK et al.
  Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment.
  N. Engl. J. Med. 2012 Dec 13;367(24):2316-21
• Wang R et al.
  RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer.
  J. Clin. Oncol. 2012 Dec 10;30(35):4352-9
• Bose R et al.
  Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer.
  Cancer Discov 2012 Dec 7.
• Guagnano V et al.
  FGFR genetic alterations predict for sensitivity to NVP-BGJ398,a selective pan-FGFR inhibitor.
  Cancer Discov. 2012 Dec;2(12):1118-33

November 2012

• Cortes JE et al.
  Ponatinib in refractory Philadelphia chromosome-positive leukemias.
  N. Engl. J. Med. 2012 Nov 29;367(22):2075-88
• Long GV et al.
  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
  Lancet Oncol. 2012 Nov;13(11):1087-95
• Levy MA et al.
  Translating genomic information into clinical medicine: Lung cancer as a paradigm.
  Genome Res. 2012 Nov;22(11):2101-8.

October 2012

• Liao X et al.
  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
  N. Engl. J. Med. 2012 Oct 25;367(17):1596-606
• Iyer G et al.
  Genome Sequencing Identifies a Basis for Everolimus Sensitivity.
  Science 2012 Oct 12;338(6104):221
• Camidge DR et al.
  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
  Lancet Oncol. 2012 Oct;13(10):1011-9

September 2012

• Janjigian YY.
  Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors
  ESMO Congress 2012
• Janne PA.
  Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers
  ESMO Congress 2012
• Mazieres J.
  Lung cancer harboring HER2 mutation: Epidemiological characteristics and therapeutic perspectives
  ESMO Congress 2012
• Arcila ME et al.
  Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas.
  Clin. Cancer Res. 2012 Sep 15;18(18):4910-8
• Greulich H et al.
  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
  Proc. Natl. Acad. Sci. U.S.A. 2012 Sep 4;109(36):14476-81
• Davies KD et al.
  Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
  Clin. Cancer Res. 2012 Sep 1;18(17):4570-9

August 2012

• Vakiani E et al.
  Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
  J. Clin. Oncol. 2012 Aug 20;30(24):2956-62
• Falchook GS et al.
  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
  Lancet Oncol. 2012 Aug;13(8):782-9
• Infante JR et al.
  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
  Lancet Oncol. 2012 Aug;13(8):773-81

July 2012

• Flaherty KT et al.
  Improved survival with MEK inhibition in BRAF-mutated melanoma
  N. Engl. J. Med. 2012 Jul 12;367(2):107-14

June 2012

• Misale S et al.
  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
  Nature. 2012 Jun 28;486(7404):532-6.
• Diaz Jr LA.
  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
  Nature. 2012 Jun 28;486(7404):537-40.

May 2012

• Sen B et al.
  Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib.
  Sci Transl Med 2012 May 30;4(136):136ra70
• Dietrich S et al.
  BRAF inhibition in refractory hairy-cell leukemia
  N. Engl. J. Med. 2012 May 24; 366(21):2038-40
• Falchook GS et al.
  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
  Lancet 2012 May 19;379(9829):1893-901
• Koskela HL et al.
  Somatic STAT3 mutations in large granular lymphocytic leukemia.
  N. Engl. J. Med. 2012 May 17;366(20):1905-13
• Yang JC et al.
  Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
  Lancet Oncol. 2012 May;13(5):539-48
• Miller VA et al.
  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
  Lancet Oncol. 2012 May;13(5):528-38

April 2012

• Janne PA et al.
  Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial
  J. Clin. Oncol. 2012 Jun 10;30(17):2063-9
• De Grève J et al.
  Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
  Lung Cancer 2012 Apr;76(1):123-7

March 2012

• Janku F et al.
  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
  J. Clin. Oncol. 2012 Mar 10;30(8):777-82
• Rosell R et al.
  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
  Lancet Oncol. 2012 Mar;13(3):239-46
• Kim Y et al.
  The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor
  Mol Cancer Ther. 2012 Mar;11(3):784-91
• Prahallad A et al.
  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
  Nature 2012 Mar 1;483(7387):100-3

February 2012

• Sosman JA et al.
  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
  N. Engl. J. Med. 2012 Feb 23;366(8):707-14
• Montagut C et al.
  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
  Nat. Med. 2012 Feb;18(2):221-3

January 2012

• Wells SA et al.
  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
  J. Clin. Oncol. 2012 Jan 10;30(2):134-41
• Pirker R et al.
  EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
  Lancet Oncol. 2012 Jan;13(1):33-42

December 2011

• Sequist LV et al.
  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.
  Ann. Oncol. 2011 Dec;22(12):2616-24

September 2011

• Sasaki T et al.
  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
  Cancer Res. 2011 Sep 15;71(18):6051-60
• Marchetti A et al.
  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
  J. Clin. Oncol. 2011 Sep 10;29(26):3574-9

August 2011

• Wagle N et al.
  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
  J. Clin. Oncol. 2011 Aug 1;29(22):3085-96
• Zhou C et al.
  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
  Lancet Oncol. 2011 Aug;12(8):735-42

July 2011

• Fukuoka M et al.
  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
  J. Clin. Oncol. 2011 Jul 20;29(21):2866-74
• Guo J et al.
  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
  J. Clin. Oncol. 2011 Jul 20;29(21):2904-9

May 2011

• Paik PK et al.
  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
  J. Clin. Oncol. 2011 May 20;29(15):2046-51

April 2011

• Long GV et al.
  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
  J. Clin. Oncol. 2011 Apr 1;29(10):1239-46